Koers PledPharma AB (publ) Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | 60,73 mln. 5,68 mln. 5,24 mln. | Omzet 2025 * | 514 mln. 48,14 mln. 44,39 mln. | Marktkapitalisatie | 2,37 mld. 222 mln. 205 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -289 mln. -27,05 mln. -24,94 mln. | Nettowinst (verlies) 2025 * | 125 mln. 11,7 mln. 10,79 mln. | EV/omzet 2024 * | 36,3 x |
Nettoliquiditeiten 2024 * | 167 mln. 15,64 mln. 14,42 mln. | Nettoliquiditeiten 2025 * | 226 mln. 21,12 mln. 19,47 mln. | EV/omzet 2025 * | 4,17 x |
K/w-verhouding 2024 * |
-7,9
x | K/w-verhouding 2025 * |
15
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 54,24% |
Recentste transcriptie over PledPharma AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 16-06-17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31-12-17 |
Chief Tech/Sci/R&D Officer | - | 05-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01-04-21 |
Director/Board Member | 50 | 01-01-20 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,99% | 115 mld. | |
+12,01% | 106 mld. | |
-3,07% | 24,69 mld. | |
-0,76% | 21,97 mld. | |
-4,87% | 19,27 mld. | |
-6,90% | 17,56 mld. | |
-39,36% | 17,32 mld. | |
+5,82% | 14,03 mld. | |
+33,05% | 12,13 mld. |
- Beurs
- Aandelen
- Koers EGTX
- Koers